Nidufexor (LMB-763) is a drug which acts as a partial agonist of the farnesoid X receptor (FXR). It has reached Phase II clinical trials for the treatment of diabetic nephropathy and nonalcoholic steatohepatitis.[1][2]
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.15.229.140